A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.

Slični predmeti

• Preclinical antihypertensive efficacy and immunogenicity in humans of a vaccine against angiotensin II based on virus-like particles (VLPs)
  od: Tissot, A, i dr.
  Izdano: (2005)
• A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.
  od: Maurer, P, i dr.
  Izdano: (2005)
• Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
  od: Tissot, A, i dr.
  Izdano: (2008)
• CYT006-AngQb, a vaccine against hypertension targeting angiotensin II, reduces early-morning and day-time blood pressure
  od: Tissot, A, i dr.
  Izdano: (2007)
• Vaccination against angiotensin II reduces day-time ambulatory blood pressure: Results of a randomized placebo-controlled phase IIA study with CYT006-ANGQB
  od: Tissot, A, i dr.
  Izdano: (2007)